
H.C. Wainwright raised the firm’s price target on Greenwich LifeSciences (GLSI) to $70 from $69 and keeps a Buy rating on the shares. The firm updated the company’s model post
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GLSI | Greenwich LifeSciences | 19.25 | 11.32 | 142.82% |
| Name | Price | % Change | |
|---|---|---|---|
| $19.25 | +142.82% |

H.C. Wainwright raised the firm’s price target on Greenwich LifeSciences (GLSI) to $70 from $69 and keeps a Buy rating on the shares. The firm updated the company’s model post

Greenwich LifeSciences (GLSI)’ Board of Directors has extended the lock-up of the shares owned by the company’s directors, officers, and existing pre-IPO investors to January 31, 2027 which is approximately

Greenwich LifeSciences (GLSI) announced the regulatory approval to expand FLAMINGO-01 into the U.K. The Company’s application to expand FLAMINGO-01 into the UK has been formally approved by UK regulators, thus

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Greenwich LifeSciences (GLSI) to $69 from $50 and keeps a Buy rating on the shares. Greenwich LifeSciences received FDA

Greenwich LifeSciences (GLSI) provided the following clinical updates on FLAMINGO-01. The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification. On December 22, 2025,

Greenwich LifeSciences (GLSI) provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe. The company previously announced that US clinical sites started enrolling

Greenwich LifeSciences (GLSI) presents the published abstract and poster from the ASCO annual meeting. The abstract is shown below. This is the second abstract and poster presented jointly with the

Greenwich LifeSciences (GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. “The Form 10-K for the fiscal year ending December 31, 2025,

Greenwich LifeSciences (GLSI) provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025. The Form 10-K for the fiscal year ending December 31, 2025

Greenwich LifeSciences announced that on April 16, the company received notification from Nasdaq notifying the company that, because it has not yet filed its annual report on Form 10-K for
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.